EARS vs. CALC, TLPH, XLO, NERV, NRBO, NRSN, GLTO, KALA, MIRA, and CNTX
Should you be buying Auris Medical stock or one of its competitors? The main competitors of Auris Medical include CalciMedica (CALC), Talphera (TLPH), Xilio Therapeutics (XLO), Minerva Neurosciences (NERV), NeuroBo Pharmaceuticals (NRBO), NeuroSense Therapeutics (NRSN), Galecto (GLTO), KALA BIO (KALA), MIRA Pharmaceuticals (MIRA), and Context Therapeutics (CNTX). These companies are all part of the "medical" sector.
CalciMedica (NASDAQ:CALC) and Auris Medical (NASDAQ:EARS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Auris Medical received 411 more outperform votes than CalciMedica when rated by MarketBeat users. However, 100.00% of users gave CalciMedica an outperform vote while only 58.00% of users gave Auris Medical an outperform vote.
CalciMedica currently has a consensus target price of $18.67, suggesting a potential upside of 345.51%. Given Auris Medical's higher probable upside, equities analysts plainly believe CalciMedica is more favorable than Auris Medical.
CalciMedica's return on equity of 0.00% beat Auris Medical's return on equity.
6.0% of Auris Medical shares are owned by institutional investors. 53.3% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, CalciMedica had 2 more articles in the media than Auris Medical. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Auris Medical. Auris Medical's average media sentiment score of 1.43 beat CalciMedica's score of 0.05 indicating that CalciMedica is being referred to more favorably in the media.
CalciMedica has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Auris Medical has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Summary
CalciMedica beats Auris Medical on 7 of the 12 factors compared between the two stocks.
Get Auris Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Auris Medical Competitors List
Related Companies and Tools